Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Elevance Health arrives at Tuesday's Q3 earnings with its stock 16% above the July post-results low, but options positioning has quietly shifted toward the most defensive stance of the past year.
The put/call ratio climbed to 0.97 on October 15, touching the 52-week high, before settling back to 0.97 on Friday's close. At 0.97 against a 20-day average of 0.89, the ratio is running nearly 1.8 standard deviations above its recent mean. That is the most pronounced lean toward downside protection since the Q2 print triggered a 13% single-day drop in July. The stock itself has held up well through the week, adding almost 4% to close at $428.26, but the options market is clearly not treating the recovery as a reason to relax. Short interest, by contrast, tells a quieter story: it has fallen 21% over the past month to just 2.1% of the free float, borrow availability is effectively uncapped, and cost to borrow at 0.45% remains minimal despite a modest uptick over the past week. The lending market is not signalling any particular conviction from bears.
The analyst community is cautiously constructive but far from uniformly bullish. Guggenheim and Barclays both raised targets in the run-up to this print, to $460 and $469 respectively, while the consensus sits at a Hold with a mean target of $451. The bull case centres on Medicare Advantage margin expansion of more than 150 basis points in 2026, a strong D-SNP membership mix, and the pricing leverage that comes with being the largest Blue Cross Blue Shield operator in the country. Bears point to the Medicaid margin outlook, ongoing commercial market pressures, and an EPS estimate for 2026 that analysts have already trimmed materially. The forward earnings multiple at roughly 14.7 times is not demanding, but the 89th-percentile ranking on forward EPS growth momentum suggests the Street is already pricing in a recovery, leaving limited room for disappointment.
One piece of context has shifted since the previous preview published on October 11: the stock has gained a further $15, meaning CEO Gail Boudreaux's July open-market purchases at $366 to $368 are now sitting on a gain of nearly 17%. Those discretionary buys, made the session after the worst earnings reaction in recent memory, remain the most concrete expression of insider conviction in the setup. Wellington Management added nearly one million shares through August, and T. Rowe Price added 228,000 through September, giving institutional buyers some company in that view.
Tuesday's print will test whether the managed care recovery ELV has priced in can survive contact with the actual medical cost and Medicaid margin data, or whether the options market's defensive tilt this week turns out to have read the room correctly.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
